Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicus PharmaMDCX -10.53%13 3-Year ROIIC % is 511.98 as of Dec. 2025, which is 68% above its 10-year median of 305.21. GuruFocus rates MDCX with a GF Score™ of 13/100. The stock has 2 warning signs investors should review. Among 944 Drug Manufacturers companies, Medicus Pharma ranks better than 97.56% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Medicus Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 511.98%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Medicus Pharma's 3-Year ROIIC % or its related term are showing as below:
MDCX's 3-Year ROIIC % is ranked better than 97.56% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs MDCX: 511.98
Medicus Pharma (NAS:MDCX) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Medicus Pharma 3-Year ROIIC % Related Terms
Medicus Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Medicus Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDCX vs NSRX, MIRA, SCLX: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, Medicus Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicus Pharma 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicus Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Medicus Pharma's 3-Year ROIIC % falls into.
Medicus Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -34.359 (Dec. 2025) - -0.978 (Dec. 2022) )
/
( 5.861 (Dec. 2025) - 12.381 (Dec. 2022) )
=
-33.381
/
-6.52
=
511.98%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Medicus Pharma (MDCX) has a 3-Year ROIIC % of 511.98 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medicus Pharma and its competitors. This is 68% above median its historical median of 305.21. Over the past decade, Medicus Pharma's 3-Year ROIIC % has ranged from 98.43 to 511.98. According to the industry distribution chart, Medicus Pharma ranks #23 out of 944 companies in the Drug Manufacturers industry, placing it in the top 2.4%.
Is Medicus Pharma's 3-Year ROIIC % too high?
Medicus Pharma's current 3-Year ROIIC % of 511.98 is 68% above median its 10-year median of 305.21. Over the past 10 years, this metric has ranged from a low of 98.43 to a high of 511.98. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Medicus Pharma's value of 511.98 is 13984.7% above this industry median. Based on the distribution chart, Medicus Pharma ranks #23 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medicus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Medicus Pharma's 3-Year ROIIC % compare to NSRX and MIRA?
According to the Drug Manufacturers industry distribution chart, Medicus Pharma ranks #23 out of 944 companies for 3-Year ROIIC %. This places Medicus Pharma in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.64. Medicus Pharma's value of 511.98 is 13984.7% above this benchmark. Historically, Medicus Pharma's own 3-Year ROIIC % has ranged from 98.43 to 511.98 over the past decade. While the company's 10-year median is 305.21 vs. the industry median of 3.64, Medicus Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicus Pharma's current 3-Year ROIIC % of 511.98 is 13984.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medicus Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicus Pharma's current 3-Year ROIIC % is 511.98, which is 68% above median its own 10-year median of 305.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicus Pharma stock overvalued right now?
Medicus Pharma (MDCX) has a current 3-Year ROIIC % of 511.98. The current 3-Year ROIIC % is 511.98, which is 68% above median its 10-year median of 305.21 and 13984.7% above the Drug Manufacturers industry median of 3.64. Medicus Pharma's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Medicus Pharma (MDCX), the current 3-Year ROIIC % is 511.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
13GF Score
Get the complete analysis for MDCX
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCX has been successfully added to your 
